Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Altius Institute for Biomedical Sciences has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 4 distinct examiners and 4 distinct art units, so prosecution is distributed across separate examination assignments.
HASAN, KHALEDA B is the busiest examiner, with 1 pending matter. No single examiner accounts for a concentration of the pending work, making matter-specific tracking important for coordinating responses across the portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (50%) |
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASAN, KHALEDA B | 1 | 59.3% | +49.0% |
| GROOMS, TIFFANY NICOLE | 1 | 57.8% | +46.3% |
| HUMPHRIES, NICHOLAS ADAM | 1 | 34.2% | +76.6% |
| LEITH, NANCY J | 1 | 74.7% | +44.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17793793 | Novel Erythroid Specific Enhancers and Uses Thereof | HUMPHRIES, NICHOLAS ADAM | 77d |
| 18554417 | DNA Binding Proteins for Regulating Gene Expression | HASAN, KHALEDA B | — |
| 18033000 | Cell Permeable Proteins for Genome Engineering | GROOMS, TIFFANY NICOLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17632365 | Compositions and Methods for Modulation of Gene Expression | LEITH, NANCY J | 6d |
| 17793793 | Novel Erythroid Specific Enhancers and Uses Thereof | HUMPHRIES, NICHOLAS ADAM | 77d |
| 18554417 | DNA Binding Proteins for Regulating Gene Expression | HASAN, KHALEDA B | — |
| 18033000 | Cell Permeable Proteins for Genome Engineering | GROOMS, TIFFANY NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1637 | 1 |
| 1631 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18554417 | DNA Binding Proteins for Regulating Gene Expression | HASAN, KHALEDA B | 1646 | §101§103§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18033000 | Cell Permeable Proteins for Genome Engineering | GROOMS, TIFFANY NICOLE | 1637 | §103§112 | Non-Final OA | — | Pending | Apr 20, 2023 |
| 17793793 | Novel Erythroid Specific Enhancers and Uses Thereof | HUMPHRIES, NICHOLAS ADAM | 1631 | §101§102§103§112 | Non-Final OA | 77d | Pending | Jul 19, 2022 |
| 17632365 | Compositions and Methods for Modulation of Gene Expression | LEITH, NANCY J | 1636 | §103 | Non-Final OA | 6d | Pending | Feb 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAltius Institute for Biomedical Sciences has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Khaleda B Hasan has the most, with 1 of Altius Institute for Biomedical Sciences's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
